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The glomerulopathy of sickle cell disease
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Sickle cell disease (SCD) produces many structural and functional abnormalities in the kidney, including
glomerular abnormalities. Albuminuria is the most common manifestation of glomerular damage, with a
prevalence between 26 and 68% in adult patients. The pathophysiology of albuminuria in SCD is likely
multifactorial, with contributions from hyperfiltration, glomerular hypertension, ischemia-reperfusion injury,
oxidative stress, decreased nitric oxide (NO) bioavailability, and endothelial dysfunction. Although its natural
history in SCD remains inadequately defined, albuminuria is associated with increased echocardiography-
derived tricuspid regurgitant jet velocity, systemic blood pressure, and hypertension, as well as history of
stroke, suggesting a shared vasculopathic pathophysiology. While most patients with albuminuria are
treated with angiotensin converting enzyme inhibitors/angiotensin receptor blockers, there are no published
long-term data on the efficacy of these agents. With the improved patient survival following kidney
transplantation, SCD patients with end-stage renal disease should be considered for this treatment modality.
Given the high prevalence of albuminuria and its association with multiple SCD-related clinical
complications, additional studies are needed to answer several clinically important questions in a bid to
adequately elucidate its pathophysiology, natural history, and treatment.
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 Introduction
Sickle cell disease (SCD), one of the most common monogenic disorders worldwide, results in many structural and functional abnormalities in
the kidney, including abnormalities of tubular function, hematuria, and glomerular abnormalities [1]. The kidney is particularly sensitive to the
effects of hypoxia because of its high rate of oxygen consumption [2]. Due to the presence of acidosis, hypertonicity and hypoxia in the environ-
ment of the renal medulla, this portion of the kidney is very susceptible to changes in oxygen delivery. As blood traverses the slow-moving circuit
of the medullary vasa recta, the hyperosmolar milieu may enhance dehydration of red blood cells (RBCs), allowing polymerization of sickle hemo-
globin (HbS) and resulting in vaso-occlusion and medullary microinfarction [3,4]. Indeed, microangiopathic studies show the loss of vasa recta in
older patients with SCD, with those that remain being abnormally dilated or blunted [5]. This review will focus on albuminuria, the most common
clinical manifestation of glomerular damage in SCD.
 Renal Pathology in SCD
In young SCD patients with normal renal function, the kidneys are enlarged, with a smooth capsular surface [6]. With advancing age and the
development of chronic renal failure, the kidneys become scarred and shrunken, with the capsular surface ranging from coarsely granular to
grossly distorted and scarred [6]. Unlike in normal individuals, glomerular size increases with age in SCD [6]. These enlarged, markedly hypercel-
lular glomeruli exhibit lobulation of the glomerular tuft on histological examination. In the early stages of sickle cell nephropathy, renal biopsy
shows glomerular hypertrophy, hemosiderin deposits, and focal areas of hemorrhage or necrosis [7,8]. In later stages, interstitial inflammation,
edema, fibrosis, tubular atrophy, and papillary infarcts are commonly observed, with these changes mostly due to vascular dropout [7,8]. A multi-
center retrospective survey of 18 SCD patients (HbSS—16; HbSC—1; 1 HbSb1 thalassemia—1) who underwent renal biopsies for isolated protei-
nuria or in association with acute or progressive impairment of renal function showed focal segmental glomerulosclerosis (FSGS) in seven cases,
membranoproliferative glomerulonephritis (MPGN) in five cases, thrombotic microangiopathic glomerulopathy in three cases, and glomerular
hypertrophy with or without mesangial hypercellularity (early sickle cell disease glomerulopathy) in three cases, suggesting a wide spectrum of glo-
merular lesions in SCD [9]. Regardless of the observed morphologic lesion, glomeruli were enlarged and the capillaries were distended by sickled
RBCs. Of the seven FSGS cases, exclusive not otherwise specified (NOS) lesions were seen in three cases, NOS lesions associated with tip lesions
in two cases and two cases showed concomitant tip lesions and perihilar lesions [9]. A collapsing pattern of FSGS has also been reported [10].
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Glomerular changes that are indistinguishable from those of prolifera-
tive glomerulonephritis may be seen in SCD patients with no appa-
rent renal disease [6]. Reduplication of the basement membrane and
mesangial proliferation are also seen in SCD, especially as patients’
age. Immunofluorescence microscopy in patients with FSGS type
lesions demonstrates irregular staining for IgM and C3 in areas of
sclerosis [7,8,10], and MPGN lesions demonstrate capillary wall stain-
ing for IgG, IgM, IgA, C3, and C1q [10]. Electron microscopy of glo-
meruli in SCD patients with proteinuria or the nephrotic syndrome
show effacement of the podocyte foot processes, with occasional wrin-
kling of the capillary wall, usually associated with partial or complete
mesangial interposition [8].
Transgenic mouse models of SCD show findings similar to those
observed in human sickle cell glomerulopathy. The transgenic SAD
mouse bears the human a-globin gene and the HbS mutation, bS, as
well as bAntilles and bD-Punjab, which greatly enhance the tendency of
its hemoglobin to polymerize. The renal pathology of the SAD mouse
shows glomerular hypertrophy and mesangial sclerosis, which
increase in frequency and severity as the mice age [11]. Glomerular
damage is associated with increased levels of blood urea nitrogen and
nonselective proteinuria. Other renal changes in these mice include
hemosiderosis, cortical infarcts, and papillary necrosis. In sickle mice
that exclusively express the human a- and bS-globin (Berkeley mice),
kidney weights are increased 2-fold, and histologic analysis shows
fibrosis, atrophy, infarcts, and cysts, with increased iron deposits in
the tubular epithelium [12]. Hemizygous sickle mice expressing
human a- and bS- transgenes in combination with mouse b1/2,
show mild to severe renal lesions including glomerulonephritis,
dilated tubules, atypical tubules, tubular degeneration, mild necrosis,
and interstitial fibrosis in about 50% of mice [13]. The renal tubular
epithelium shows increased expression of inducible nitric oxide (NO)
synthase and 3-nitrotyrosine, as well as increased staining for vascular
cell adhesion molecule-1 (VCAM-1) in the interstitial capillary cells
and tubular epithelial cells compared with normal control mice.
 Pathophysiology
The relative hypoxia, acidosis, and hyperosmolarity of the inner
medulla favor polymerization of deoxygenated HbS and subsequent
sickling of RBCs. These repeated cycles of sickling are thought to lead
to ischemic injury and microinfarction, which ultimately result in
reduced medullary blood flow. Worsening hypoxia results in localized
prostaglandin release and marked vasodilation, which increases renal
blood flow and hence glomerular filtration rate (GFR). Indirect meas-
urements of renal prostaglandin activity have been performed by
observing the effects of the prostaglandin synthesis inhibitor, indo-
methacin. Following administration of indomethacin, GFR and effec-
tive renal plasma flow (ERPF) fell significantly in HbSS patients but
remained unchanged in control subjects [14], suggesting that prosta-
glandins are important in maintaining the supranormal levels of GFR
and ERPF observed in SCD. The association of increased GFR in HbSS
patients with albuminuria raises the possibility that hyperfiltration may
contribute to renal damage [15–18] (Table I). If, indeed, hyperfiltration
is a necessary precursor of glomerulopathy in SCD, then endogenous
perturbation of the prostaglandin systems could explain the early devel-
opment of FSGS in this setting. Hyperfiltration also may lead to endo-
thelial hyperplasia and ultimately glomerular fibrosis [31,32].
The pathophysiology of sickle cell glomerulopathy has been reported
to resemble that which develops in rodents following subtotal nephrec-
tomy [7,8,19]. In these animals, glomerular hypertension in the remain-
ing hypertrophied glomeruli may result in glomerular sclerosis [20].
The observation that glomerular hypertension is attenuated by angio-
tensin converting enzyme inhibitors in rodents, combined with the
quick and reversible decrease in protein excretion in HbSS patients
receiving these agents gives further credence to the possibility that this
mechanism contributes to SCD-related glomerulopathy [7,20].
Transgenic mice homozygous for the murine b-globin deletion that
carry two transgenes, aHbS and aHbS-Antilles, exhibit oxidative stress in
the kidney as indicated by increased amounts of lipid peroxidation
[21]. Exacerbation of oxidative stress increased sickling of RBCs,
extending from the medulla into the cortical capillaries and glomeruli.
In these sickle mice, renal ischemia following total renal artery occlu-
sion for 15 min resulted in a significant increase in creatinine and blood
urea nitrogen levels that was associated with diffuse acute tubular
necrosis extending across the entire width of the cortex, with large seg-
ments of cortical necrosis [22]. Six hours after bilateral renal ischemia
for 22.5 min, the sickle mice showed greater renal histological injury
than wild-type mice with extensive tubular necrosis extending from the
corticomedullary junction through the full thickness of the cortex
accompanied by marked congestion in peritubular capillaries and an
acute glomerulopathy consisting of endothelialitis and mesangiolysis
[22]. These latter changes along with accompanying reparative
responses, especially if incurred through repetitive cycles of renal ische-
mia, may contribute to a chronic glomerulopathy in SCD (Fig. 1).
Renal ischemia results in an impairment of GFR, as well as a
reduction in renal blood flow in sickle mice [23]. Ischemia results in
a failure of phosphorylation of MAPK/Akt signaling proteins, ERK1/2
(p42/44), JNK (p44/46), p38, and Akt in sickle mice. These proteins
influence inflammatory responses and cell survival, proliferation,
migration, and differentiation following ischemia, and thus modulate








bioavailability due to hemolysis
and/or increased levels of soluble
fms-like tyrosine kinase-1
[25–29]
Chronic treatment with opioid analgesics [30]
Figure 1. Proposed mechanisms of glomerulopathy in sickle cell disease.
Multiple mechanisms may contribute to the pathogenesis of glomerular
damage in sickle cell disease. These may occur due to changes in the
renal vasculature, peritubular capillaries and the glomerulus. PG: prosta-
glandins; NO: nitric oxide; ANP: atrial natriuretic peptide; ROS: reactive
oxygen species; sFLT-1: soluble fms-like tyrosine kinase-1; VEGF: vascular
endothelial growth factor; ANG-II: angiotensin II; TGF-b: transforming
growth factor-b; TNFa: tumor necrosis factor-a; ET-1: endothelin-1.
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the renal response to acute ischemic injury [23]. As the phosphoryl-
ated form of these signaling proteins usually determines the active
moiety, the recruitment of signaling processes following ischemia is
markedly impaired in the kidney of sickle mice. The impaired phos-
phorylation of mitogen-activated protein kinase (MAPK) and Akt
proteins in the kidney following ischemia may partly be due to
decreased renal ATP content and correlates with increased expression
of TNF-a, an inflammatory cytokine which may contribute to the
increased sensitivity of the kidney to ischemia in sickle mice [23].
More recent data appear to confirm the role of oxidative stress in
sickle cell glomerulopathy. Reactive oxygen species (ROS) increase the
conversion of oxidized angiotensinogen to angiotensin II (ATII), and
increase secondary angiotensin receptor 1 (AT1R)-mediated genera-
tion of transforming growth factor-beta 1 (TGF-b1) in the kidney in
SCD, which then phosphorylates Smad 2/3 [24]. In young sickle
mice, blockade of the AT1R with losartan, or its ligand ATII by an
angiotensin converting enzyme inhibitor, captopril, prevented albumi-
nuria and FSGS development but worsened hyposthenuria, suggesting
that excessive AT1R signaling causes sickle cell glomerulopathy, while
AT1R promotes urine concentrating ability. Furthermore, AT1R sig-
naling is known to activate NADPH oxidase to generate ROS and
mice treated with captopril and losartan had reduced ROS in RBC,
platelets as well as the kidneys, and consequently reduced renin-
angiotensin system activation.
The level of soluble fms-like tyrosine kinase-1 (sFLT-1) is elevated
in patients with SCD patients compared to healthy, race-matched
control subjects [33,34]. sFLT-1 is a member of the vascular endothe-
lial growth factor receptor (VEGFR) family [35] and is a splice vari-
ant of VEGFR1. VEGF, a well-known promoter of angiogenesis and
an endogenous regulator of endothelial integrity promotes endothelial
cell survival and angiogenesis through activation of the protein
kinase, Akt, which in turn activates endothelial NO synthase and
increases NO generation [36]. By antagonizing VEGF action and
inhibiting Akt phosphorylation, sFLT-1 decreases NO bioavailability,
thus leading to endothelial dysfunction. sFLT-1 has been linked with
preeclampsia, a condition characterized by hypertension, proteinuria,
and endothelial dysfunction [37]. We have shown that SCD patients
with macroalbuminuria have significantly higher levels of sFLT-1 and
soluble VCAM-1 compared to patients with lower levels of albuminu-
ria [25]. The association of albuminuria with soluble VCAM-1, com-
bined with the association of sFLT-1 with soluble VCAM-1, suggests
that sFLT-1 may contribute to the pathogenesis of albuminuria in
SCD by promoting endothelial dysfunction [25].
Multiple observational studies show an association of albuminuria
with markers of hemolysis in patients with SCD [26–29], although
other studies have not shown such associations [18,25,38,39]. Chronic
depletion of NO due, at least in part, to scavenging by cell-free hemo-
globin from ongoing intravascular hemolysis, may contribute to the
glomerulopathy in SCD. In addition, the activation of hypoxia-
inducible factor 1a and the consequent increase in local endothelin-1
release, in the presence of reduced NO, leads to an increase in ROS and
vasoconstriction, contributing to a cycle of chronic medullary hypoxia
[40,41]. We have shown an association of sFLT-1 with markers of
hemolysis [34] suggesting that sFLT-1 may be downstream of hemoly-
sis, and increased sFLT-1 levels may further decrease the bioavailability
of NO in SCD. NO deficiency has been demonstrated in individuals
with chronic kidney disease, and this may lead to progression of
chronic kidney disease [42]. Indeed, animal studies show that chronic
inhibition of NO synthase causes systemic and glomerular hyperten-
sion, glomerular ischemia, glomerulosclerosis, tubulointerstitial injury,
and proteinuria [43]. With the increasing evidence that hemolysis may
play a role in the vasculopathy of SCD [44], hemolysis and NO defi-
ciency may also contribute to the development of glomerulopathy
in SCD.
Chronic treatment of transgenic sickle mice with morphine for 3–6
weeks has been reported to produce defects in renal pathology,
including increased glomerular volume, mesangial expansion, mesan-
gial cell proliferation, parietal cell metaplasia, podocyte effacement,
and microvillus transformation [30]. Chronic treatment with mor-
phine also increased the expression and activity of heme oxygenase-1,
and increased albuminuria [30]. The renal effects of morphine are
ameliorated by naloxone, a nonselective opioid antagonist, suggesting
that opioid receptor antagonists may be effective in decreasing
morphine-induced renal disease.
 Clinical Implications
The normal rate of urinary albumin excretion is less than 20 mg/
day (15 mcg/min), and is usually between 4 and 7 mg/day in healthy
young adults. Persistent excretion of albumin between 30 and
300 mg/day (20–200 mcg/min) is called microalbuminuria, while
albumin excretion above 300 mg/day (200 mcg/min) is considered
overt proteinuria or macroalbuminuria. The standard urine dipstick
primarily detects albumin, and is only semiquantitative. While very
specific, the standard dipstick test is not sensitive to low levels of
albuminuria and will not usually identify those with microalbuminu-
ria. The gold standard for quantitative assessment of albuminuria is a
24-hr urine collection. Although proteinuria can be assessed by meas-
uring the ratio of protein-to-creatinine (or albumin-to-creatinine
ratio) from a spot first- or second-morning sample, this method has
not been validated in SCD. In a study of 25 patients with albuminu-
ria, albumin-to-creatinine ratio was reported to correlate with 12-hr
urinary albumin excretion [45]. However, no correlations were
observed in the percent change (from the first measurements) follow-
ing treatment with angiotensin converting enzyme inhibitors at the
times of second and third measurements of 12-hr urinary albumin
excretion and albumin-to-creatinine ratio [45]. In another small
study, the presence of microalbuminuria diagnosed by spot urine
albumin-to-creatinine ratio in 19 patients was confirmed by 24-hr
urine collection in only 57% of cases [46].
The prevalence of albuminuria in SCD increases with age, varying
between 4.5 and 26% in patients up to 21 years [46–52], and between
26 and 68% in older patients [7,15,25,38,53,54]. Although a prospec-
tive, 25-year case-control study reported that 9 of 21 HbSS patients
with nephrotic syndrome developed chronic renal failure [55], the
natural history of albuminuria in SCD remains inadequately defined.
A small study of 38 patients, 30 of whom had microalbuminuria and
eight with macroalbuminuria, showed progression of albuminuria in
two patients with microalbuminuria and two patients with macroal-
buminuria after approximately 20 months of follow-up [56]. In a ret-
rospective study of 14 patients, with estimated GFR at the time of
kidney biopsy ranging from 24 to 158 mL/min per m2 and urine
albumin excretion at the time of kidney biopsy ranging from 0.4 to
33 g/day, seven patients had chronic kidney disease and three patients
required chronic intermittent hemodialysis due to ESRD after an
average follow-up of 28 months (range, 4–79 months) [9]. Evaluation
for proteinuria was only available in 12 patients, and a decrease in
urinary protein was noted in 67% of patients treated with ATII recep-
tor blockers or angiotensin converting enzyme inhibitors. In a more
recent retrospective, single center study of 98 SCD patients, grade A3
albuminuria (adjusted odds ratio [OR], 5.0; 95% confidence interval
[CI], 1.1–24.3; P5 0.0480) and each 1 mm Hg increase in systolic
blood pressure (adjusted OR, 1.04; 95% CI, 1.0–1.07; P5 0.039) were
associated with the development and progression of chronic kidney
disease on multivariate analysis after 5 years of follow-up [57]. In this
study, grade A3 proteinuria was defined as a urine protein-to-
creatinine ratio greater than 500 mg/g, based on the 2012 KDIGO
clinical practice guidelines [58].
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Albuminuria is more prevalent in HbSS patients than in those
with other sickling hemoglobinopathies [38] and is associated with
echocardiography-derived tricuspid regurgitant jet velocity
[25,54,59,60], increased systemic blood pressure and hypertension
[15,38,54,61], and history of stroke [25,48]. These associated comor-
bidities suggest a shared vasculopathic pathophysiology with albumi-
nuria [25–29]. Albuminuria is also reported to be associated with
asymptomatic bacteruria [52], as well as a history of acute chest syn-
drome [46,54] and cholelithiasis [48], likely reflecting the role of
hemolysis in the pathogenesis of albuminuria. Finally, a recent multi-
center cross-sectional study reported an association of proteinuria,
assessed by dipstick, with early mortality [62] (Table II).
 Treatment
Improved medical care for individuals with SCD has prolonged
their survival, resulting in an increased prevalence of end-organ dam-
age. Albuminuria occurs more commonly with increasing age and
may progress to ESRD. Progression to ESRD is often preceded by
increasing proteinuria, worsening anemia, and/or the appearance of
hypertension [55]. There are no large, controlled studies demonstrat-
ing the efficacy of any interventions for albuminuria in SCD. How-
ever, treatment of 10 HbSS patients who had proteinuria (0.8–10.8 g/
day) with the angiotensin converting enzyme inhibitor, enalapril, for
2 weeks decreased the rate of urinary protein excretion in all patients
at the end of the treatment period [7]. This observation was con-
firmed in a 6-month study in eight HbSS patients with albuminuria
[63]. In a double-blind, placebo-controlled study of 22 HbSS patients
with microalbuminuria, treatment with captopril resulted in a
decrease in microalbuminuria from baseline, while an increase in
microalbuminuria was observed in the placebo group [64]. Based on
these limited data, angiotensin converting enzyme inhibitors and/or
angiotensin receptor blockers have become the “standard of care” for
the treatment of albuminuria in SCD (Table III). However, adequately
powered controlled studies of these agents are required to evaluate
whether they can halt the progression of SCD glomerulopathy and
subsequent chronic kidney disease. Hyperkalemia and renal tubular
acidosis may occur as manifestations of SCD nephropathy and the
use of angiotensin converting enzyme inhibitor therapy may increase
the likelihood of hyperkalemia. As such, other effective agents without
this side effect are needed in patients with albuminuria. Angiotensin
receptor blocking agents are increasingly used instead of angiotensin
converting enzyme inhibitors because of their improved tolerability,
although there are no published data in SCD to date. Two clinical
trials of the angiotensin receptor blocker, losartan, are ongoing
(NCT01989078, NCT01479439).
Therapies that improve RBC survival, such as hydroxyurea, or
those that improve endothelial function may be beneficial. In a retro-
spective study, three HbSS children with nephrotic range proteinuria
on treatment with enalapril had a near-normal urine protein-
creatinine ratio following the addition of hydroxyurea [65]. Further
observational studies suggest that hydroxyurea may reduce albuminu-
ria and slow the development of hyperfiltration [50,54,66]. Young age
at start of chronic RBC transfusion has also been suggested to pro-
vide protection against the development of albuminuria [45],
although there are no controlled studies in this setting.
As nonsteroidal anti-inflammatory agents can produce significant
declines in the rates of glomerular filtration and renal blood flow in
SCD [67,68], and can increase the rate of progression to ESRD, these
agents should be used with caution in patients with evidence of glomer-
ulopathy. In addition, effective treatment of hypertension has been
reported to delay the progression to ESRD in SCD patients [69], and
careful attention to blood pressure control is important in these
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association with renal insufficiency as well as other complications [70–
73], there are no guidelines for its treatment in patients with SCD. SCD
patients can generally be treated like other adults with hypertension,
although diuretics should be used with caution to avoid dehydration,
which may precipitate acute painful episodes in these patients.
In SCD patients who develop ESRD, renal replacement therapies
(hemodialysis and peritoneal dialysis) as well as renal transplantation
are available treatment modalities. Predialysis nephrology care in
patients with ESRD is associated with a lower death rate compared
with those not receiving such care [74], and early referral to a nephrol-
ogist is recommended. While some reports have indicated poor allo-
graft survival as well as a variety of disease-specific problems [75],
others have found graft and patient survival rates comparable to those
of other nondiabetic ESRD patients [76]. Short-term allograft results
have been reported to be comparable in SCD patients and age-
matched African-American kidney transplant recipients with other
causes of ESRD, although there was a somewhat shorter cadaveric graft
survival and a greater adjusted 3-year risk of graft loss in SCD patients
beyond 1 year [77]. Furthermore, there was a trend toward improved
survival when renal transplantation was compared to chronic dialysis
in patients with ESRD secondary to sickle cell nephropathy.
A report based on data from the United Network for Organ Shar-
ing registry reported patient survival at 3 years among the SCD kid-
ney recipients of 75%, with these kidney recipients having a 7.9 times
higher risk of posttransplant death compared with patients trans-
planted for IgA nephropathy (95% CI: 4.3–14.5) [78]. However, it has
been suggested that IgA nephropathy may not be the appropriate ref-
erence condition to compare to SCD as it is uncommon in African-
Americans [79,80]. When kidney transplant recipients of African
descent were stratified by transplant era (1988–1999 vs. 2000–2011)
using data from the Organ Procurement and Transplantation Net-
work/United Network for Organ Sharing, patient survival at 6 years
was lower in SCD patients in the earlier era compared to other
patient groups (55.7 % vs. 78%, P< 0.001), with an improvement in
the 6-year survival of SCD patients in the more recent era compared
to other patient groups (69.8% versus 80%, P5 0.07) [81]. Although
still lower than recipients with hypertensive kidney disease and glo-
merulonephritis, survival of SCD kidney recipients over 6 years was
comparable to that of recipients with diabetes.
Renal transplantation may be complicated further by the resump-
tion of frequent painful episodes, possibly due to an increase in whole
blood viscosity that accompanies higher posttransplantation hemato-
crit levels [82]; posttransplantation renal allograft thrombosis and
infarction [83]; and the development of sickle cell nephropathy in the
donor kidney [84].
Despite these various therapeutic modalities, the prevention of
sickle cell glomerulopathy and subsequent chronic kidney disease ulti-
mately depends upon the development of an early cure for SCD.
Until gene therapy fulfills its enormous promise, the only currently
available curative modality for SCD is bone marrow transplantation
(BMT). However, the availability of BMT remains limited. The ability
to confidently identify those young patients who are at the highest
risk for severe disease will make it possible to select the most appro-
priate candidates for BMT long before end-organ damage becomes
manifest. In addition, early involvement of nephrologists in the treat-
ment of patients with albuminuria may be beneficial.
 Conclusions and Need for Future
Studies
SCD is often complicated by a glomerulopathy, which commonly
manifests as albuminuria. Although the natural history of albuminuria
in SCD remains poorly defined, patients who exhibit albuminuria are
more likely to develop ESRD. With the association of ESRD and an
increased risk of mortality, early identification and treatment of albu-
minuria may decrease the risk of death in SCD. Further, due to its asso-
ciation with other SCD-related complications, albuminuria may be a
useful biomarker for vasculopathic complications in SCD. The patho-
physiology of albuminuria in SCD is likely multifactorial, with contri-
butions from hyperfiltration, glomerular hypertension, ischemia-
reperfusion injury, oxidative stress, decreased NO bioavailability, and
endothelial dysfunction. Although most patients with albuminuria are
treated with angiotensin converting enzyme inhibitors/angiotensin
receptor blockers, there are no long-term data on the efficacy of these
agents. With the limited data on these agents, combined with their side
effect profile, other treatment agents are needed. In view of the
improved patient survival following kidney transplantation, more SCD
patients with ESRD should be considered for this treatment modality.
Given the high prevalence of albuminuria and its association with
multiple SCD-related clinical complications, additional studies are
clearly required to answer several clinically important questions in a
bid to elucidate its pathophysiology, natural history, and treatment.
What are the long-term renal consequences of albuminuria in SCD? Is
spot urine quantification of albuminuria reliable in SCD? Can albumi-
nuria serve as a suitable biomarker of renal and other vasculopathic
complications in SCD? Will screening for microalbuminuria detect kid-
ney disease earlier? Will treatment of microalbuminuria delay the pro-
gression to overt proteinuria and chronic kidney disease in SCD? Does
treatment with opioid analgesics worsen albuminuria in SCD? Does
treatment of proteinuria with angiotensin converting enzyme inhibi-
tors/angiotensin receptor blockers lead to long-term benefit and attenu-
ation of chronic kidney disease? Do hydroxyurea and other agents that
improve RBC survival, increase NO bioavailability and improve endo-
thelial function have a role in the treatment of SCD glomerulopathy?
Only through carefully designed clinical and laboratory studies will
these questions be answered.
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TABLE III. Evaluation and Treatment of Albuminuria in Sickle Cell Disease
 Screening for albuminuria by standard dipstick urinalysis
(with serum creatinine) at least yearly.
 Albuminuria detected by dipstick urinalysis should be quantified
by 24-hr urine collection (or spot urine for protein-to-creatinine ratioa).
 In patients with overt proteinuria, HIV, RPR, hepatitis B, hepatitis C,
complements, and antinuclear antibodies should be
measured and urine sediment evaluated, particularly for presence
of RBC casts, as they may suggest other diagnoses. Serum protein
electrophoresis and/or serum free light chains should also be
measured in older patients. Consider a renal biopsy if acute onset of
nephrotic range proteinuria.
 Avoid use of NSAIDs.
 Adequate immunization—pneumococcal and influenza.
 Consider use of ACE inhibitors or ARBs, if there are no
contraindications. Provide counseling regarding dietary potassium
intake and monitor potassium following initiation.
 Consider use of hydroxyurea, especially in patients with history of
frequent pain episodes, acute chest syndrome, or marked anemia.
a This method has not been validated in SCD.
HIV5Human immunodeficiency virus; RPR5Rapid plasma reagin; NSAIDs5
Nonsteroidal anti-inflammatory drugs; ACE inhibitors5angiotensin convert-
ing enzyme inhibitors; ARBs5Angiotensin receptor blockers.
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